van Meerbeeck Jan P, Surmont Veerle F M
Department of Respiratory Medicine & Thoracic Oncology, University Hospital, Ghent, Belgium.
Lung Cancer. 2009 Sep;65(3):257-67. doi: 10.1016/j.lungcan.2009.02.007. Epub 2009 Mar 13.
Few issues are as controversial in non-small cell lung cancer as the management of patients with stage IIIA-N2 non-small cell lung cancer. This manuscript reviews the reasons and the biases inherent to this controversy and discusses the different treatment approaches with emphasis on survival as evidenced by meta-analyses and large randomised clinical trials. Prospects on novel treatment modalities and future research opportunities are presented.
在非小细胞肺癌中，很少有问题像IIIA-N2期非小细胞肺癌患者的治疗那样具有争议性。本文回顾了这一争议背后的原因和内在偏差，并讨论了不同的治疗方法，重点是荟萃分析和大型随机临床试验所证明的生存率。文中还介绍了新型治疗模式的前景和未来的研究机会。
